230 related articles for article (PubMed ID: 17109348)
1. Clinical and immunologic risk factors for meningococcal C conjugate vaccine failure in the United Kingdom.
Auckland C; Gray S; Borrow R; Andrews N; Goldblatt D; Ramsay M; Miller E
J Infect Dis; 2006 Dec; 194(12):1745-52. PubMed ID: 17109348
[TBL] [Abstract][Full Text] [Related]
2. Persistence of serum bactericidal antibody one year after a booster dose of either a glycoconjugate or a plain polysaccharide vaccine against serogroup C Neisseria meningitidis given to adolescents previously immunized with a glycoconjugate vaccine.
de Whalley PC; Snape MD; Kelly DF; Banner C; Lewis S; Diggle L; John TM; Yu LM; Omar O; Borkowski A; Pollard AJ
Pediatr Infect Dis J; 2011 Nov; 30(11):e203-8. PubMed ID: 21673612
[TBL] [Abstract][Full Text] [Related]
3. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
4. Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease.
Souza AR; Maruyama CM; Sáfadi MA; Lopes MH; Azevedo RS; Findlow H; Bai X; Borrow R; Weckx LY
Vaccine; 2016 Aug; 34(36):4327-34. PubMed ID: 27395566
[TBL] [Abstract][Full Text] [Related]
5. Salivary antibody levels in adolescents in response to a meningococcal serogroup C conjugate booster vaccination nine years after priming: systemically induced local immunity and saliva as potential surveillance tool.
Stoof SP; van der Klis FR; van Rooijen DM; Bogaert D; Trzciński K; Sanders EA; Berbers GA
Vaccine; 2015 Jul; 33(32):3933-9. PubMed ID: 26100925
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of Meningococcal Serogroup C-Specific Functional Antibody Levels Up to 15 Years after a Single Immunization with a Meningococcal Serogroup C Conjugate Vaccine during Adolescence.
Stoof SP; van Ravenhorst MB; van Rooijen DM; de Voer RM; van der Klis FRM; Boland GJ; Sanders EAM; Berbers GAM; Teunis PF
Clin Vaccine Immunol; 2017 Feb; 24(2):. PubMed ID: 27881489
[TBL] [Abstract][Full Text] [Related]
7. Antibody persistence after serogroup C meningococcal conjugate immunization of United Kingdom primary-school children in 1999-2000 and response to a booster: a phase 4 clinical trial.
Perrett KP; Winter AP; Kibwana E; Jin C; John TM; Yu LM; Borrow R; Curtis N; Pollard AJ
Clin Infect Dis; 2010 Jun; 50(12):1601-10. PubMed ID: 20459323
[TBL] [Abstract][Full Text] [Related]
8. Is a single infant priming dose of meningococcal serogroup C conjugate vaccine in the United Kingdom sufficient?
Findlow H; Borrow R
Hum Vaccin Immunother; 2015; 11(6):1501-6. PubMed ID: 25912095
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of meningococcal serogroup C conjugate vaccine programs in Canadian children: interim analysis.
Bettinger JA; Scheifele DW; Halperin SA; Kellner JD; Vanderkooi OG; Schryvers A; De Serres G; Alcantara J
Vaccine; 2012 Jun; 30(27):4023-7. PubMed ID: 22537988
[TBL] [Abstract][Full Text] [Related]
10. Long-term seroprotection after an adolescent booster meningococcal serogroup C vaccination.
de Whalley PC; Snape MD; Plested E; Thompson B; Nuthall E; Omar O; Borrow R; Pollard AJ
Arch Dis Child; 2013 Sep; 98(9):686-91. PubMed ID: 23853000
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
12. Randomized Trial to Compare the Immunogenicity and Safety of a CRM or TT Conjugated Quadrivalent Meningococcal Vaccine in Teenagers who Received a CRM or TT Conjugated Serogroup C Vaccine at Preschool Age.
Ishola DA; Andrews N; Waight P; Yung CF; Southern J; Bai X; Findlow H; Matheson M; England A; Hallis B; Findlow J; Borrow R; Miller E
Pediatr Infect Dis J; 2015 Aug; 34(8):865-74. PubMed ID: 26075813
[TBL] [Abstract][Full Text] [Related]
13. A decade of herd protection after introduction of meningococcal serogroup C conjugate vaccination.
Bijlsma MW; Brouwer MC; Spanjaard L; van de Beek D; van der Ende A
Clin Infect Dis; 2014 Nov; 59(9):1216-21. PubMed ID: 25069869
[TBL] [Abstract][Full Text] [Related]
14. A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide--CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challenge phase.
Riddell A; Buttery JP; McVernon J; Chantler T; Lane L; Bowen-Morris J; Diggle L; Morris R; Lockhart S; Pollard AJ; Cartwright K; Moxon ER
Vaccine; 2007 May; 25(19):3906-12. PubMed ID: 17368663
[TBL] [Abstract][Full Text] [Related]
15. The development of a new heptavalent diphtheria-tetanus-whole cell pertussis-hepatitis B-Haemophilus influenzae type b-Neisseria meningitidis serogroups A and C vaccine: a randomized dose-ranging trial of the conjugate vaccine components.
Gatchalian S; Palestroque E; De Vleeschauwer I; Han HH; Poolman J; Schuerman L; Dobbelaere K; Boutriau D
Int J Infect Dis; 2008 May; 12(3):278-88. PubMed ID: 17981067
[TBL] [Abstract][Full Text] [Related]
16. Antibody persistence and immunological memory at age 4 years after meningococcal group C conjugate vaccination in children in the United kingdom.
Borrow R; Goldblatt D; Andrews N; Southern J; Ashton L; Deane S; Morris R; Cartwright K; Miller E
J Infect Dis; 2002 Nov; 186(9):1353-7. PubMed ID: 12402208
[TBL] [Abstract][Full Text] [Related]
17. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
[TBL] [Abstract][Full Text] [Related]
18. Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: reevaluation of correlates of protection.
Borrow R; Andrews N; Goldblatt D; Miller E
Infect Immun; 2001 Mar; 69(3):1568-73. PubMed ID: 11179328
[TBL] [Abstract][Full Text] [Related]
19. Long-term persistence of protective antibodies in Dutch adolescents following a meningococcal serogroup C tetanus booster vaccination.
van Ravenhorst MB; Marinovic AB; van der Klis FR; van Rooijen DM; van Maurik M; Stoof SP; Sanders EA; Berbers GA
Vaccine; 2016 Dec; 34(50):6309-6315. PubMed ID: 27817957
[TBL] [Abstract][Full Text] [Related]
20. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults.
Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E
Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
